{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:04:39Z","timestamp":1770321879694,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,29]],"date-time":"2014-05-29T00:00:00Z","timestamp":1401321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/bjc.2014.236","type":"journal-article","created":{"date-parts":[[2014,5,29]],"date-time":"2014-05-29T22:48:10Z","timestamp":1401403690000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment"],"prefix":"10.1038","volume":"111","author":[{"given":"D","family":"Generali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F M","family":"Buffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Deb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L E","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Andreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Allevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S R","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S B","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,29]]},"reference":[{"issue":"4","key":"BFbjc2014236_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/sj.bjc.6603593","volume":"96","author":"NL Barnes","year":"2007","unstructured":"Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96 (4): 575\u2013582.","journal-title":"Br J Cancer"},{"issue":"21","key":"BFbjc2014236_CR2","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2006.06.1366","volume":"24","author":"N Bijker","year":"2006","unstructured":"Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853\u2014a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24 (21): 3381\u20133387.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BFbjc2014236_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/sj.bjc.6601534","volume":"90","author":"GP Boland","year":"2004","unstructured":"Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90 (2): 423\u2013429.","journal-title":"Br J Cancer"},{"issue":"7","key":"BFbjc2014236_CR4","first-page":"2751","volume":"6","author":"A Bottini","year":"2000","unstructured":"Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L (2000) p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6 (7): 2751\u20132758.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"BFbjc2014236_CR5","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","volume":"24","author":"A Bottini","year":"2006","unstructured":"Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24 (22): 3623\u20133628.","journal-title":"J Clin Oncol"},{"issue":"17","key":"BFbjc2014236_CR6","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1158\/0008-5472.CAN-11-0489","volume":"71","author":"FM Buffa","year":"2011","unstructured":"Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71 (17): 5635\u20135645.","journal-title":"Cancer Res"},{"issue":"5","key":"BFbjc2014236_CR7","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-09-1623","volume":"16","author":"NJ Bundred","year":"2010","unstructured":"Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM (2010) Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 16 (5): 1605\u20131612.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"BFbjc2014236_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1073\/pnas.2535911100","volume":"101","author":"SH Chang","year":"2004","unstructured":"Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101 (2): 591\u2013596.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1-2","key":"BFbjc2014236_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jsbmb.2008.04.004","volume":"111","author":"LW Chow","year":"2008","unstructured":"Chow LW, Yip AY, Loo WT, Lam CK, Toi M (2008) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111 (1-2): 13\u201317.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"BFbjc2014236_CR10","first-page":"2651","volume":"9","author":"G Davies","year":"2003","unstructured":"Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M (2003) Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9 (7): 2651\u20132656.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"BFbjc2014236_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1200\/JCO.2007.13.3744","volume":"26","author":"LY Dirix","year":"2008","unstructured":"Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M, Abbattista A, Lobelle JP (2008) Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 26 (8): 1253\u20131259.","journal-title":"J Clin Oncol"},{"issue":"41","key":"BFbjc2014236_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"2010","author":"C Correa","year":"2010","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG),, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010 (41): 162\u2013177.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"9169","key":"BFbjc2014236_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (9169): 1993\u20132000.","journal-title":"Lancet"},{"issue":"1","key":"BFbjc2014236_CR14","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/bcr2825","volume":"13","author":"SB Fox","year":"2011","unstructured":"Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL (2011) The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Res 13 (1): R16.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"BFbjc2014236_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2007.13.7083","volume":"27","author":"D Generali","year":"2009","unstructured":"Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB (2009) Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 27 (2): 227\u2013234.","journal-title":"J Clin Oncol"},{"issue":"6","key":"BFbjc2014236_CR16","first-page":"1676","volume":"62","author":"E Half","year":"2002","unstructured":"Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62 (6): 1676\u20131681.","journal-title":"Cancer Res"},{"issue":"41","key":"BFbjc2014236_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jncimonographs\/lgq022","volume":"2010","author":"RL Kane","year":"2010","unstructured":"Kane RL, Virnig BA, Shamliyan T, Wang SY, Tuttle TM, Wilt TJ (2010) The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010 (41): 130\u2013133.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"7553","key":"BFbjc2014236_CR18","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (7553): 1302\u20131308.","journal-title":"BMJ"},{"issue":"9","key":"BFbjc2014236_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jnci\/djq101","volume":"102","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102 (9): 627\u2013637.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"BFbjc2014236_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/jcp.53.8.634","volume":"53","author":"R Leake","year":"2000","unstructured":"Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R (2000) Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 53 (8): 634\u2013635.","journal-title":"J Clin Pathol"},{"issue":"12","key":"BFbjc2014236_CR21","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/jnci\/djh164","volume":"96","author":"GD Leonard","year":"2004","unstructured":"Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96 (12): 906\u2013920.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"BFbjc2014236_CR22","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1007\/s13277-013-0840-x","volume":"34","author":"F Lin","year":"2013","unstructured":"Lin F, Luo J, Gao W, Wu J, Shao Z, Wang Z, Meng J, Ou Z, Yang G (2013) COX-2 promotes breast cancer cell radioresistance via p38\/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol 34 (5): 2817\u20132826.","journal-title":"Tumour Biol"},{"issue":"4","key":"BFbjc2014236_CR23","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1097\/00000421-200308002-00013","volume":"26","author":"W Liu","year":"2003","unstructured":"Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I (2003) Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 26 (4): S103\u2013S109.","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"BFbjc2014236_CR24","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-11-1877","volume":"18","author":"A McIntyre","year":"2012","unstructured":"McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, Leek R, Snell C, Gatter K, Sly WS, Vaughan-Jones RD, Swietach P, Harris AL (2012) Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 18 (11): 3100\u20133111.","journal-title":"Clin Cancer Res"},{"issue":"36","key":"BFbjc2014236_CR25","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","volume":"23","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 (36): 9067\u20139072.","journal-title":"J Clin Oncol"},{"issue":"12","key":"BFbjc2014236_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/modpathol.3800229","volume":"17","author":"SK Mohsin","year":"2004","unstructured":"Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, To TV, Qian Z, Love RR, Allred DC (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17 (12): 1545\u20131554.","journal-title":"Mod Pathol"},{"issue":"9","key":"BFbjc2014236_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1470-2045(06)70861-0","volume":"7","author":"K Mokbel","year":"2006","unstructured":"Mokbel K, Cutuli B (2006) Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol 7 (9): 756\u2013765.","journal-title":"Lancet Oncol"},{"issue":"4","key":"BFbjc2014236_CR28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ijrobp.2003.08.032","volume":"58","author":"JK O'Connor","year":"2004","unstructured":"O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK (2004) Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 58 (4): 1034\u20131040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"BFbjc2014236_CR29","first-page":"632","volume":"62","author":"A Ristimaki","year":"2002","unstructured":"Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62 (3): 632\u2013635.","journal-title":"Cancer Res"},{"issue":"4","key":"BFbjc2014236_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/sj.bjc.6600741","volume":"88","author":"G Spizzo","year":"2003","unstructured":"Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88 (4): 574\u2013578.","journal-title":"Br J Cancer"},{"issue":"20","key":"BFbjc2014236_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djn324","volume":"100","author":"B Takkouche","year":"2008","unstructured":"Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100 (20): 1439\u20131447.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"BFbjc2014236_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bjc.6604844","volume":"100","author":"EY Tan","year":"2009","unstructured":"Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, Harris AL, Fox SB (2009) The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100 (2): 405\u2013411.","journal-title":"Br J Cancer"},{"issue":"6","key":"BFbjc2014236_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","volume":"103","author":"IL Wapnir","year":"2011","unstructured":"Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103 (6): 478\u2013488.","journal-title":"J Natl Cancer Inst"},{"issue":"part 2","key":"BFbjc2014236_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. J R Statist Soc B 67 (part 2): 301\u2013320.","journal-title":"J R Statist Soc B"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014236","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:23:14Z","timestamp":1684416194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFbjc2014236"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.236","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,29]]},"assertion":[{"value":"30 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}